PRECISELY Targeted Therapies for patients with cancer

With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.

Chemistry at the Core

We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.

Built for Patients

We partner with physician-scientists to identify patient needs and the limitations of existing therapies.

Driven by Purpose

We are passionate about using our expertise to address the needs of patients with cancer.

Ruth Adams
Clinical Operations
Ruth Adams
Ruth Adams
Clinical Operations
Benjamin Lane, PhD
Pharmaceutical Development
Benjamin Lane, PhD
Benjamin Lane, PhD
Pharmaceutical Development
Baudouin Gerard, PhD
Medicinal Chemistry
Baudouin Gerard, PhD
Baudouin Gerard, PhD
Medicinal Chemistry
Kristi Byrnes
Quality Assurance
Kristi Byrnes
Quality Assurance
Stephen McNamara
Finance
Stephen McNamara
Finance
Anupong
Tangpeerachaikul, PhD
Biology
Anupong Tangpeerachaikul, PhD
Anupong
Tangpeerachaikul, PhD
Biology
Deb Miller, PhD, JD
Chief Legal Officer
Deb Miller, PhD, JD
Chief Legal Officer
John Soglia, PhD
Translational Development
John Soglia, PhD
John Soglia, PhD
Translational Development
Yuting Sun, PhD
Biology
Yuting Sun, PhD
Biology
Alex Balcom
Chief Financial Officer
Alex Balcom
Alex Balcom
Chief Financial Officer
Kristin Andrews, PhD
Computational Chemistry
Kristin Andrews, PhD
Kristin Andrews, PhD
Computational Chemistry
Viola Zhu, MD, PhD
Clinical Development
Viola Zhu, MD, PhD
Clinical Development
James Porter, PhD
Chief Executive Officer
James Porter, PhD
James Porter, PhD
Chief Executive Officer
Tuan Minh Nguyen, PhD
Biology
Tuan Minh Nguyen, PhD
Biology
Darlene Noci, ALM
Product Development
& Regulatory Affairs
Darlene Noci, ALM
Darlene Noci, ALM
Product Development
& Regulatory Affairs
Jason Kropp
Pharmaceutical Development
Jason Kropp
Jason Kropp
Pharmaceutical Development
Ray Kemper, PhD
Toxicology
Ray Kemper, PhD
Toxicology
Matthew Campbell
Pharmaceutical Development
Matthew Campbell
Pharmaceutical Development
Christopher Turner, MD
Chief Medical Officer
Christopher Turner, MD
Chief Medical Officer
Virginia Vetter
Regulatory Affairs
Virginia Vetter
Regulatory Affairs
Scot Mente, PhD
Computational Chemistry
Scot Mente, PhD
Scot Mente, PhD
Computational Chemistry
Henry Pelish, PhD
Biology
Henry Pelish, PhD
Henry Pelish, PhD
Biology
Joshua Horan, PhD
Chemistry
Joshua Horan, PhD
Joshua Horan, PhD
Chemistry